RT Journal Article T1 Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Trypanosoma cruzi Mitochondrion. A1 Martín-Escolano, Rubén A1 Molina-Carreño, Daniel A1 Plano, Daniel A1 Espuelas, Socorro A1 Rosales, María J A1 Moreno, Esther A1 Aydillo, Carlos A1 Sanmartín, Carmen A1 Sánchez-Moreno, Manuel A1 Marín, Clotilde K1 American trypanosomiasis K1 Trypanosoma cruzi K1 chagas disease K1 chemotherapy K1 drug discovery K1 neglected tropical diseases K1 screening cascade K1 selenium derivatives K1 target product profile AB Chagas disease is usually caused by tropical infection with the insect-transmitted protozoan Trypanosoma cruzi. Currently, Chagas disease is a major public health concern worldwide due to globalization, and there are no treatments neither vaccines because of the long-term nature of the disease and its complex pathology. Current treatments are limited to two obsolete drugs, benznidazole and nifurtimox, which lead to serious drawbacks. Taking into account the urgent need for strict research efforts to find new therapies, here, we describe the in vitro and in vivo trypanocidal activity of a library of selected forty-eight selenocyanate and diselenide derivatives that exhibited leishmanicidal properties. The inclusion of selenium, an essential trace element, was due to the well-known extensive pharmacological activities for selenium compounds including parasitic diseases as T. cruzi. Here we present compound 8 as a potential compound that exhibits a better profile than benznidazole both in vitro and in vivo. It shows a fast-acting behaviour that could be attributed to its mode of action: it acts in a mitochondrion-dependent manner, causing cell death by bioenergetic collapse. This finding provides a step forward for the development of a new antichagasic agent. SN 1424-8247 YR 2021 FD 2021-05-01 LK http://hdl.handle.net/10668/17859 UL http://hdl.handle.net/10668/17859 LA en DS RISalud RD Apr 20, 2025